Elevated serum tartrate-resistant acid phosphatase isoform 5a levels in metabolic syndrome

Yi Jhih Huang, Tsai Wang Huang, Tsu Yi Chao, Yu Shan Sun, Shyi Jou Chen, Der Ming Chu, Wei Liang Chen, Li Wei Wu

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Tartrate-resistant phosphatase isoform 5a is expressed in tumorassociated macrophages and is a biomarker of chronic inflammation. Herein, we correlated serum tartrate-resistant phosphatase isoform 5a levels with metabolic syndrome status and made comparisons with traditional markers of inflammation, including c-reactive protein and interleukin-6. Methods: One hundred healthy volunteers were randomly selected, and cut-offpoints for metabolic syndrome related inflammatory biomarkers were determined using receiver operating characteristic curves. Linear and logistic regression models were subsequently used to correlate inflammatory markers with the risk of metabolic syndrome. Results: Twenty-two participants met the criteria for metabolic syndrome, and serum tartrate-resistant phosphatase isoform 5a levels of > 5.8 μg/L were associated with metabolic syndrome (c-statistics, 0.730; p = 0.001; 95% confidence interval, 0.618-0.842). In addition, 1 μg/L increases in tartrate-resistant phosphatase isoform 5a levels were indicative of a 1.860 fold increase in the risk of metabolic syndrome (p = 0.012). Conclusions: Elevated serum tartrate-resistant phosphatase isoform 5a levels are associated with the risk of metabolic syndrome, with a cut-offlevel of 5.8 μg/L.

Original languageEnglish
Pages (from-to)78144-78152
Number of pages9
JournalOncotarget
Volume8
Issue number44
DOIs
Publication statusPublished - 2017

Fingerprint

Protein Isoforms
Phosphoric Monoester Hydrolases
Serum
Biomarkers
Logistic Models
Inflammation
Tartrate-Resistant Acid Phosphatase
ROC Curve
Linear Models
Interleukin-6
Healthy Volunteers
Macrophages
tartaric acid
Confidence Intervals
Proteins

Keywords

  • Metabolic syndrome
  • Tartrate-resistant acid phosphatase

ASJC Scopus subject areas

  • Oncology

Cite this

Huang, Y. J., Huang, T. W., Chao, T. Y., Sun, Y. S., Chen, S. J., Chu, D. M., ... Wu, L. W. (2017). Elevated serum tartrate-resistant acid phosphatase isoform 5a levels in metabolic syndrome. Oncotarget, 8(44), 78144-78152. https://doi.org/10.18632/oncotarget.17839

Elevated serum tartrate-resistant acid phosphatase isoform 5a levels in metabolic syndrome. / Huang, Yi Jhih; Huang, Tsai Wang; Chao, Tsu Yi; Sun, Yu Shan; Chen, Shyi Jou; Chu, Der Ming; Chen, Wei Liang; Wu, Li Wei.

In: Oncotarget, Vol. 8, No. 44, 2017, p. 78144-78152.

Research output: Contribution to journalArticle

Huang, YJ, Huang, TW, Chao, TY, Sun, YS, Chen, SJ, Chu, DM, Chen, WL & Wu, LW 2017, 'Elevated serum tartrate-resistant acid phosphatase isoform 5a levels in metabolic syndrome', Oncotarget, vol. 8, no. 44, pp. 78144-78152. https://doi.org/10.18632/oncotarget.17839
Huang, Yi Jhih ; Huang, Tsai Wang ; Chao, Tsu Yi ; Sun, Yu Shan ; Chen, Shyi Jou ; Chu, Der Ming ; Chen, Wei Liang ; Wu, Li Wei. / Elevated serum tartrate-resistant acid phosphatase isoform 5a levels in metabolic syndrome. In: Oncotarget. 2017 ; Vol. 8, No. 44. pp. 78144-78152.
@article{5f3903208b1c48bea50a031e9ac06489,
title = "Elevated serum tartrate-resistant acid phosphatase isoform 5a levels in metabolic syndrome",
abstract = "Background: Tartrate-resistant phosphatase isoform 5a is expressed in tumorassociated macrophages and is a biomarker of chronic inflammation. Herein, we correlated serum tartrate-resistant phosphatase isoform 5a levels with metabolic syndrome status and made comparisons with traditional markers of inflammation, including c-reactive protein and interleukin-6. Methods: One hundred healthy volunteers were randomly selected, and cut-offpoints for metabolic syndrome related inflammatory biomarkers were determined using receiver operating characteristic curves. Linear and logistic regression models were subsequently used to correlate inflammatory markers with the risk of metabolic syndrome. Results: Twenty-two participants met the criteria for metabolic syndrome, and serum tartrate-resistant phosphatase isoform 5a levels of > 5.8 μg/L were associated with metabolic syndrome (c-statistics, 0.730; p = 0.001; 95{\%} confidence interval, 0.618-0.842). In addition, 1 μg/L increases in tartrate-resistant phosphatase isoform 5a levels were indicative of a 1.860 fold increase in the risk of metabolic syndrome (p = 0.012). Conclusions: Elevated serum tartrate-resistant phosphatase isoform 5a levels are associated with the risk of metabolic syndrome, with a cut-offlevel of 5.8 μg/L.",
keywords = "Metabolic syndrome, Tartrate-resistant acid phosphatase",
author = "Huang, {Yi Jhih} and Huang, {Tsai Wang} and Chao, {Tsu Yi} and Sun, {Yu Shan} and Chen, {Shyi Jou} and Chu, {Der Ming} and Chen, {Wei Liang} and Wu, {Li Wei}",
year = "2017",
doi = "10.18632/oncotarget.17839",
language = "English",
volume = "8",
pages = "78144--78152",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "44",

}

TY - JOUR

T1 - Elevated serum tartrate-resistant acid phosphatase isoform 5a levels in metabolic syndrome

AU - Huang, Yi Jhih

AU - Huang, Tsai Wang

AU - Chao, Tsu Yi

AU - Sun, Yu Shan

AU - Chen, Shyi Jou

AU - Chu, Der Ming

AU - Chen, Wei Liang

AU - Wu, Li Wei

PY - 2017

Y1 - 2017

N2 - Background: Tartrate-resistant phosphatase isoform 5a is expressed in tumorassociated macrophages and is a biomarker of chronic inflammation. Herein, we correlated serum tartrate-resistant phosphatase isoform 5a levels with metabolic syndrome status and made comparisons with traditional markers of inflammation, including c-reactive protein and interleukin-6. Methods: One hundred healthy volunteers were randomly selected, and cut-offpoints for metabolic syndrome related inflammatory biomarkers were determined using receiver operating characteristic curves. Linear and logistic regression models were subsequently used to correlate inflammatory markers with the risk of metabolic syndrome. Results: Twenty-two participants met the criteria for metabolic syndrome, and serum tartrate-resistant phosphatase isoform 5a levels of > 5.8 μg/L were associated with metabolic syndrome (c-statistics, 0.730; p = 0.001; 95% confidence interval, 0.618-0.842). In addition, 1 μg/L increases in tartrate-resistant phosphatase isoform 5a levels were indicative of a 1.860 fold increase in the risk of metabolic syndrome (p = 0.012). Conclusions: Elevated serum tartrate-resistant phosphatase isoform 5a levels are associated with the risk of metabolic syndrome, with a cut-offlevel of 5.8 μg/L.

AB - Background: Tartrate-resistant phosphatase isoform 5a is expressed in tumorassociated macrophages and is a biomarker of chronic inflammation. Herein, we correlated serum tartrate-resistant phosphatase isoform 5a levels with metabolic syndrome status and made comparisons with traditional markers of inflammation, including c-reactive protein and interleukin-6. Methods: One hundred healthy volunteers were randomly selected, and cut-offpoints for metabolic syndrome related inflammatory biomarkers were determined using receiver operating characteristic curves. Linear and logistic regression models were subsequently used to correlate inflammatory markers with the risk of metabolic syndrome. Results: Twenty-two participants met the criteria for metabolic syndrome, and serum tartrate-resistant phosphatase isoform 5a levels of > 5.8 μg/L were associated with metabolic syndrome (c-statistics, 0.730; p = 0.001; 95% confidence interval, 0.618-0.842). In addition, 1 μg/L increases in tartrate-resistant phosphatase isoform 5a levels were indicative of a 1.860 fold increase in the risk of metabolic syndrome (p = 0.012). Conclusions: Elevated serum tartrate-resistant phosphatase isoform 5a levels are associated with the risk of metabolic syndrome, with a cut-offlevel of 5.8 μg/L.

KW - Metabolic syndrome

KW - Tartrate-resistant acid phosphatase

UR - http://www.scopus.com/inward/record.url?scp=85027877597&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027877597&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.17839

DO - 10.18632/oncotarget.17839

M3 - Article

AN - SCOPUS:85027877597

VL - 8

SP - 78144

EP - 78152

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 44

ER -